IOncology

The “YBCSG 2025 Mid-Year Breast Cancer Collaboration Meeting and Post-ASCO Symposium,” held recently in Shanghai, gathered experts to discuss clinical updates in breast cancer treatment. At the event, Prof. Hengyu Li—Secretary General of the Yangtze River Breast Cancer Study Group (YBCSG) and a leading expert at Shanghai Changhai Hospital, Naval Medical University—delivered a comprehensive presentation titled “Treatment Challenges of Breast Cancer Liver Metastases in 2025.” In an exclusive interview with Oncology Frontier, Prof. Li elaborated on YBCSG’s major achievements in the first half of 2025 and highlighted key challenges in managing liver metastases in breast cancer.

The 2025 Annual Conference of the Chinese Society of Clinical Oncology (BOC) and Best of ASCO® 2025 China (BOC/BOA) will be held on July 4–5 in Nanjing. This year’s event coincides with the 10th anniversary of the China Clinical Oncology Annual Research Progress publication—marking a key milestone in China's oncology journey. Over the past decade, the field has witnessed robust growth, and BOC/BOA has emerged as a vital academic bridge linking global innovations with local practice. This year’s conference will bring together leading experts from around the world to review the remarkable achievements of the past ten years and explore future directions in cancer care.

At the recent "Yangtze Breast Cancer Collaboration Mid-Year Meeting and the Mid-Year Meeting of the Oncology Drug Clinical Research Committee of the Chinese Medical Education Association," Professor Leiping Wang from Fudan University Shanghai Cancer Center delivered a keynote presentation titled “New Advances in HER2-Positive Breast Cancer at ASCO 2025 and My Clinical Practice.” Oncology Frontier invited Prof. Wang for an exclusive interview to share insights on the key findings presented at the ASCO 2025 conference in the field of HER2-positive breast cancer and their clinical implications, along with perspectives on future research directions.

Editor’s Note: At the recent “Yangtze River Academic Breast Cancer Mid-Year Exchange Conference & CSOE Tumor Drug Clinical Research Committee Mid-Year Meeting & 2025 ASCO Debrief,” Professor Ting Li from…

Editor’s Note: The DESTINY-Breast09 (DB-09) study, recently presented at the ASCO Annual Meeting, has sparked widespread attention among oncology experts and is poised to reshape the first-line treatment landscape for…

Editor’s Note: Triple-negative breast cancer (TNBC), characterized by its distinct biology and limited treatment targets, remains one of the most challenging and intensely studied subtypes of breast cancer. At the…

Fifth Bincheng Multidisciplinary Breast Cancer Conference Editor’s Note: The Fifth Bincheng Multidisciplinary Breast Cancer Conference, hosted by the First Affiliated Hospital of Dalian Medical University, was recently held with great…

Hubei Association of Radiation Oncology Physicians 2025 Academic Conference Editor’s Note: The 2025 Annual Academic Conference of the Radiation Oncology Physicians Branch of the Hubei Medical Association was recently held…